Forte Biosciences, Inc.·4

Jul 6, 4:03 PM ET

Wagner Paul A. 4

Research Summary

AI-generated summary

Updated

Forte Biosciences CEO Paul Wagner Converts 1,250 RSUs; 98 Shares Withheld

What Happened

  • Paul A. Wagner — CEO, Secretary and Chair of Forte Biosciences (FBRX) — had 1,250 restricted stock units (RSUs) convert into 1,250 shares on July 1, 2026. To cover tax withholding, 98 of those shares were surrendered at $21.32 per share, generating $2,089 in withholding proceeds. The remaining shares were delivered to Wagner. This is an RSU vesting/conversion event (not an open-market purchase or sale).

Key Details

  • Transaction date: July 1, 2026 (reported on Form 4 filed July 6, 2026).
  • Vesting/conversion: 1,250 RSUs converted into 1,250 common shares (derivative conversion, code M).
  • Tax withholding: 98 shares withheld/disposed at $21.32 per share for $2,089 (code F).
  • Reported disposed entry of 1,250 shares at $0 reflects the RSU-to-share conversion mechanics on the Form 4 (derivative reporting).
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Footnotes:
    • F1: Each RSU represents a contingent right to receive one share of common stock.
    • F2: RSUs vest quarterly per the 2021 Equity Incentive Plan (one-sixteenth on each Quarterly Vesting Date beginning Feb 1, 2023).
  • Timeliness: Filed five days after the transaction date; this is beyond the typical two-business-day Form 4 deadline and may be considered late.

Context

  • This was a routine RSU vesting event. The withholding of 98 shares to satisfy tax obligations is common and should not be confused with an intentional sale of shares for investment purposes.
  • For retail investors, RSU conversions indicate insiders receiving company stock as compensation; they do not, by themselves, signal a buy or sell decision.